Response
We thank Dr Rosenthal for his letter and agree that our article 1 should not encourage the use of sildenafil in patients with Eisenmenger's syndrome. Although in our patient sildenafil was beneficial, this is only an isolated case. Most importantly, our trial was not placebo-controlled, and until blinded and placebocontrolled data are available, sildenafil should not be used routinely in patients with Eisenmenger's syndrome or any form of pulmonary arterial hypertension (PAH). Our pilot data should only encourage research in this area and perhaps inclusion of patients with congenital heart disease and PAH in larger clinical trials; unfortunately, patients with PAH and congenital heart disease are often excluded from PAH trials. The modern management of PAH dictates referral to physicians specializing in PAH or to multidisciplinary pulmonary hypertension clinics in major tertiary care centers.
